<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Matos L</submitter><funding>Associazione Italiana di Oncologia Medica</funding><funding>Instituto de Salud Carlos III</funding><pagination>104558</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12683136</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>84</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS.&lt;h4>Methods&lt;/h4>International cross-sectional online survey for patients and physicians, distributed from May 2023 to February 2024. Patients with BC diagnosis were deemed eligible for patients' survey completion and BC-treating physicians were invited to fill the physicians' questionnaire.&lt;h4>Results&lt;/h4>A total of 529 physicians from 50 countries (80 % European) responded, mostly medical oncologists (70 %) working in academic hospitals (53 %). Most physicians request BIS (65 %), </pubmed_abstract><journal>Breast (Edinburgh, Scotland)</journal><pubmed_title>Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.</pubmed_title><pmcid>PMC12683136</pmcid><funding_grant_id>JR24/00024</funding_grant_id><pubmed_authors>le Du F</pubmed_authors><pubmed_authors>Morgan G</pubmed_authors><pubmed_authors>Haidinger R</pubmed_authors><pubmed_authors>Rodriguez Recio G</pubmed_authors><pubmed_authors>Muller V</pubmed_authors><pubmed_authors>Criscitiello C</pubmed_authors><pubmed_authors>Brucker S</pubmed_authors><pubmed_authors>Laakmann E</pubmed_authors><pubmed_authors>Matos L</pubmed_authors><pubmed_authors>Fontes Sousa M</pubmed_authors><pubmed_authors>Schettini F</pubmed_authors><pubmed_authors>Jerzak KJ</pubmed_authors><pubmed_authors>Dieras V</pubmed_authors><pubmed_authors>Lambertini M</pubmed_authors><pubmed_authors>von Kroge P</pubmed_authors><pubmed_authors>Braga S</pubmed_authors><pubmed_authors>Schumacher-Wulf E</pubmed_authors><pubmed_authors>Linn S</pubmed_authors><pubmed_authors>van Ramshorst M</pubmed_authors><pubmed_authors>Agostinetto E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.</name><description>&lt;h4>Background&lt;/h4>Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS.&lt;h4>Methods&lt;/h4>International cross-sectional online survey for patients and physicians, distributed from May 2023 to February 2024. Patients with BC diagnosis were deemed eligible for patients' survey completion and BC-treating physicians were invited to fill the physicians' questionnaire.&lt;h4>Results&lt;/h4>A total of 529 physicians from 50 countries (80 % European) responded, mostly medical oncologists (70 %) working in academic hospitals (53 %). Most physicians request BIS (65 %), </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T00:16:08.396Z</modification><creation>2026-05-23T03:13:58.857Z</creation></dates><accession>S-EPMC12683136</accession><cross_references><pubmed>40849221</pubmed><doi>10.1016/j.breast.2025.104558</doi></cross_references></HashMap>